Home / News

News

Responsable des Activités de Pharmacologie/Immunologie...

Responsable des Activités de Pharmacologie/Immunologie Clinique Société biopharmaceutique à taille humaine développant des produits innovants d’immunothérapie…

Read more

Invectys at JP Morgan 36th Annual Healthcare Conference...

January 8 – 11, 2018 J.P. Morgan 36th Annual Healthcare Conference 2018 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…

Read more

FDA approval to launch INVAC-1 Phase II clinical trial

Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…

Read more

4,3 Millions d’Euros de levés pour initier la Phase II

Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux   Paris, le 12…

Read more

Invectys presents its INVAC-1 therapeutic vaccine Phase...

Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…

Read more

BIO€QUITY Europe, Paris May 22, 23

Invectys will attend to the 18th annual BIO€QUITY Europe Meet Invectys there ! More information:  invest@invectys.com 18TH ANNUAL BIO€QUITY EUROPE Bio€quity…

Read more

Invectys at the Third International Symposium on Immuno...

Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…

Read more

Invectys at ASCO 2017 in Chicago : Clinical Oncology

Invectys attend ASCO 2017 meeting in Chicago  Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…

Read more